Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and γ-aminobutyric acid receptors

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 5, 2009, Pages 524.e1-524.e4

  Vink, Joy ^a,c   Incerti, Maddelena ^a   Toso, Laura ^b   Roberson, Robin ^a   Abebe, Daniel ^a   Spong, Catherine Y ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Down syndrome; learning; N methyl D aspartic acid; NAPVSIPQ; SALLRSIPA; Ts65Dn; aminobutyric acid

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; ASPARAGINYLALANYLPROLYLVALYLSERYLISOLEUCYLPROLYLGLUTAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PLACEBO; POLYPEPTIDE; SERYLALANYLLEUCYLLEUCYLARGINYLSERYLISOLEUCYLPROLYLALANINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DOWN SYNDROME; DRUG MECHANISM; FEMALE; GESTATIONAL AGE; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 64249116198     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.01.052     Document Type: Article

References (26)

1. Genetics. In: Cunningham F.G., Leveno K.J., Bloom S.L., Hauth J.C., Gilstrap L.C., and Wenstrom K.D. (Eds). Williams obstetrics. 22nd ed. (2005), McGraw-Hill, New York 290
2. Toso L., Cameroni I., Schmidt C., Abebe D., Bissell S., and Spong C.Y. Prevention of developmental delays in a Down syndrome model. Obstet Gynecol 112 (2008) 1242-1251
3. Bassan M., Zamostiano R., Davidson A., et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem 72 (1999) 1283-1293
4. Giladi E., Hill J.M., Dresner E., Stack C.M., and Gozes I. Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. J Mol Neurosci 33 (2007) 278-283
5. Gozes I., Zamostiano R., Pinhasov A., et al. A novel VIP responsive gene: activity dependent neuroprotective protein. Ann N Y Acad Sci 921 (2000) 115-118
6. Brenneman D.E., Spong C.Y., Hauser J.M., et al. Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther 309 (2004) 1190-1197
7. Spong C.Y., Abebe D., Gozes I., and Brenneman D.E. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J Pharmacol Exp Ther 297 (2001) 774-779
8. Vink J., Auth J., Abebe D., Brenneman D.E., and Spong C.Y. Novel peptides prevent alcohol-induced spatial learning deficits and pro-inflammatory cytokine release in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol 193 (2005) 825-829
9. Toso L., Endres M., Vink J., Abebe D.T., Brenneman D.E., and Spong C.Y. Learning enhancement with neuropeptides. Am J Obstet Gynecol 194 (2006) 1153-1159
10. Hill J.M., Ades A.M., McCune S.K., et al. Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome. Exp Neurol 183 (2003) 56-65
11. Reeves R.H., Irving N.G., Moran T.H., et al. A mouse model for Down syndrome exhibits learning and behavior deficits. Nat Genet 11 (1995) 177-184
12. Demas G.E., Nelson R.J., Krueger B.K., and Yarowsky P.G. Spatial memory deficits in segmental trisomic Ts65Dn mice. Behav Brain Res 82 (1996) 85-92
13. Demas G.E., Nelson R.J., Krueger B.K., and Yarowsky P.G. Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice. Behav Brain Res 90 (1998) 100-201
14. Holtzman D.M., Santucci D., Kilbridge J., et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A 93 (1996) 13333-13338
15. Escorihuela R.M., Vallina I.F., Martinez-Cue C., et al. Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 247 (1998) 171-174
16. Sago H., Carlson E.J., Smith D.J., et al. Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome. Pediatr Res 48 (2000) 606-613
17. Hyde L.A., Frisone D.F., and Crnic L.S. Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. Behav Brain Res 118 (2001) 53-60
18. Belichenko P.V., Masliah E., Kleschevnikov A.M., et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. J Comp Neurol 480 (2004) 281-298
19. Contestabile A., Fila T., Ceccarelli C., et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 17 (2007) 665-678
20. Best T.K., Siarey R.J., and Galdzicki Z. Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. J Neurophysiol 97 (2007) 892-900
21. Spong C.Y., Lee S.J., McCune S.K., et al. Maternal regulation of embryonic growth: the role of vasoactive intestinal peptide. Endocrinology 140 (1999) 917-924
22. Perez-Otano I., and Ehlers D. Learning from NMDA receptor trafficking: clues to the development and maturation of glutamatergic synapses. Neurosignals 3 (2004) 175-189
23. Freund T.F., and Buzsaki G. Interneurons of the hippocampus. Hippocampus 6 (1996) 347-470
24. Barker J.L., Behar T., Li Y.X., et al. GABAertic cells and signals in CNS development. Perspect Dev Neurobiol 5 (1998) 305-322
25. Mehta A.K., and Ticku M. An update on GABAA receptors. Brain Res 29 (1999) 196-217
26. Toso L., Poggi S.H., Roberson R., et al. Prevention of alcohol-induced learning deficits in fetal alcohol syndrome mediated through NMDA and GABA receptors. Am J Obstet Gynecol 194 (2006) 681-686